In its submission to the Independent Review of Intellectual Property and Growth, the UK’s leading business group - the Confederation of British Industry - said that the intellectual property (IP) framework is fundamental to supporting the nation’s world-class IP-intensive sectors, including pharmaceuticals, aerospace, commercial goods and the creative industries.
Copyright, a particular focus of the review, is the lifeblood of Britain’s creative industries, and should not be eroded. In the digital age, new technologies are changing how information is distributed, and we must ensure that people’s ideas are protected. Wholesale changes to the IP framework could damage confidence, reduce the incentive for further investment, and threaten growth.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze